Loading...
XHELREG1V
Market cap745mUSD
Dec 20, Last price  
26.86EUR
1D
1.90%
1Q
-21.60%
Jan 2017
164.37%
Name

Revenio Group Oyj

Chart & Performance

D1W1MN
XHEL:REG1V chart
P/E
37.38
P/S
7.40
EPS
0.72
Div Yield, %
1.34%
Shrs. gr., 5y
2.13%
Rev. gr., 5y
25.80%
Revenues
97m
-0.41%
32,002,96922,591,22318,444,36011,456,00045,146,00029,977,00029,434,00033,281,00025,382,00025,727,00016,031,00020,250,00023,434,00026,791,00030,658,00049,474,00061,067,00078,778,00096,976,00096,576,000
Net income
19m
-12.15%
0002,272,0002,665,000-815,000-507,0003,911,000-287,0004,338,000-694,0006,497,0005,584,0006,850,0008,103,0009,343,00013,362,00017,321,00021,753,00019,109,000
CFO
11m
-53.26%
0001,001,0003,279,0001,956,0001,274,0004,229,000774,0005,483,0002,763,0006,811,0006,046,0007,870,00010,416,00012,489,00015,230,00021,509,00023,241,00010,862,000
Dividend
Apr 05, 20240.38 EUR/sh
Earnings
Feb 13, 2025

Profile

Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; DRSplus, a device for detection of diabetic retinopathy; iCare MAIA, a microperimeter to measure the visual field; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. It also provides Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
URL
https://www.reveniogroup.fi/
IPO date
Jan 01, 2003
Employees
217
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
96,576
-0.41%
96,976
23.10%
78,778
29.00%
Cost of revenue
43,770
41,450
34,704
Unusual Expense (Income)
NOPBT
52,806
55,526
44,074
NOPBT Margin
54.68%
57.26%
55.95%
Operating Taxes
6,274
7,303
4,778
Tax Rate
11.88%
13.15%
10.84%
NOPAT
46,532
48,223
39,296
Net income
19,109
-12.15%
21,753
25.59%
17,321
29.63%
Dividends
(9,572)
(9,036)
(8,498)
Dividend yield
1.32%
0.88%
0.58%
Proceeds from repurchase of equity
275
BB yield
-0.02%
Debt
Debt current
5,563
5,080
23,523
Long-term debt
16,017
16,860
2,616
Deferred revenue
Other long-term liabilities
702
739
777
Net debt
(2,298)
(10,715)
728
Cash flow
Cash from operating activities
10,862
23,241
21,509
CAPEX
(653)
(1,996)
(2,215)
Cash from investing activities
(5,975)
(2,155)
(13,538)
Cash from financing activities
(15,006)
(14,141)
(12,140)
FCF
35,263
44,138
40,231
Balance
Cash
21,542
32,062
25,216
Long term investments
2,336
593
195
Excess cash
19,049
27,806
21,472
Stockholders' equity
101,625
92,823
80,579
Invested Capital
99,462
83,116
80,906
ROIC
50.97%
58.80%
52.24%
ROCE
43.36%
48.46%
41.58%
EV
Common stock shares outstanding
26,593
26,580
26,557
Price
27.18
-29.59%
38.60
-30.51%
55.55
10.44%
Market cap
722,792
-29.55%
1,026,002
-30.45%
1,475,267
10.18%
EV
720,494
1,015,287
1,475,995
EBITDA
56,750
58,960
47,694
EV/EBITDA
12.70
17.22
30.95
Interest
763
263
223
Interest/NOPBT
1.44%
0.47%
0.51%